Precision BioSciences (NASDAQ:DTIL) is a biotechnology firm dedicated to improving lives through its proprietary genome editing platform, ARCUS. This innovative company is engaged in the development of novel therapeutics and solutions in the field of gene editing, with a keen focus on overcoming cancer and genetic diseases. Precision BioSciences is actively working on a range of projects including but not limited to, next-generation CAR T-cell therapies aimed at addressing unmet medical needs in oncology, and gene therapies to tackle rare genetic disorders. The company's objectives are rooted in leveraging its cutting-edge technology to create precise, targeted treatments that offer a significant advantage over existing therapies, ultimately striving to deliver revolutionary medical breakthroughs and improve patient outcomes.